ATROVENT NASAL SPRAY 0.06% Rx
Generic Name and Formulations:
Ipratropium bromide 0.06% (42mcg/spray); aqueous soln.
Boehringer Ingelheim Pharmaceuticals
Indications for ATROVENT NASAL SPRAY 0.06%:
Rhinorrhea associated with the common cold.
Adults and Children:
<5yrs: not recommended. 5–11yrs: 2 sprays in each nostril 3 times daily. ≥12yrs: 2 sprays in each nostril 3–4 times daily.
Allergy to atropine or its derivatives.
Avoid eyes. Narrow-angle glaucoma. GI or GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Epistaxis, dry mouth or throat, nasal congestion or dryness.
Nasal spray—15mL (165 sprays)
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness